Presbyopia is an age-related eye condition that causes visual impairment gradually. The disease has been described as "an irreversible optical failure, an unexplained evolutionary blunder that comes as a psychologic shock”. Though not incapacitating if corrected, presbyopia without optical correction results in an inability to perform once-effortless near tasks at a customary working distance without experiencing visual symptoms. The disease can result from the gradual decrease in the amplitude of accommodation. There are three different theories on how ciliary muscle contraction alters zonular tension to increase the optical power of the lens during accommodation.
PRESBYOPIA DRUG CANDIDATES UNDER DEVELOPMENT (2018)
It has been observed that presbyopia mostly occurs in the elderly population or geriatric patients. It is therefore important that the route of administration is the easiest. It has also been observed that most of the drug candidates are being developed to be administered by the topical route, which can be viewed as one of the opportunities for the development of presbyopia therapeutics. Further, most of the drug candidates have received or have filed for patent covering a novel mechanism for the treatment of presbyopia. For instance, the USPTO granted U.S. Patent No. US 9089562B2 to Presbyopia Therapies LLC for tropicamide/aceclidine in the U.S. entitled "compositions and methods for the treatment of presbyopia." Patent approval helps in increasing opportunities for invention improvement and uniqueness.
The presbyopia therapeutics pipeline comprises of nine drug candidates, in different stages of development.
Some of the key players developing Novartis AG, Allergan Plc, and ORASIS Pharmaceuticals Ltd.